JP2024030671A - Oral composition - Google Patents

Abstract

An object of the present invention is to provide an oral composition that has an excellent oral biofilm bactericidal effect, contains vitamin E stably even after storage, and has excellent stability. [Solution] (A) isopropyl methylphenol, (B) one or more selected from acylamino acids, acyl taurine, and salts thereof, and (C) one selected from tocopherol, esters thereof with organic acids, and salts thereof. An oral composition comprising the above and (D) pyrrolidone carboxylic acid or a salt thereof. [Selection diagram] None

Description

The present invention relates to an oral composition that has an excellent oral biofilm bactericidal effect, contains vitamin E stably even after storage, and has excellent stability.

In oral compositions, sterilizing oral biofilm and promoting gum activation is effective in preventing or suppressing periodontal disease.
Isopropyl methylphenol, a nonionic disinfectant, has an oral biofilm bactericidal effect, and as a technique for improving its effect, for example, adding an acyl taurine salt and a nonion to a liquid oral composition containing isopropyl methylphenol and cetylpyridinium chloride. It has been proposed that the combination of surfactants can improve the ability to penetrate periodontal pathogenic biofilms and kill airborne bacteria (Patent Document 1; Japanese Patent No. 6413815).
On the other hand, vitamin E is known as a medicinal ingredient that activates the gums by promoting blood flow and restoring tissue, and is included in toothpaste compositions for preventing or suppressing periodontal disease. It is difficult to stably incorporate vitamin E, which has sexual properties, into oral compositions. To address these issues, we added polyoxyethylene alkyl ether with an average number of moles of ethylene oxide added of 3 to 8, an alkyl group having 16 to 18 carbon atoms, and ethylene oxide to a dentifrice composition containing vitamin E or its derivatives. By incorporating a surfactant mixture in which polyoxyethylene hydrogenated castor oil with an average added mole number of 10 to 80 is mixed and dispersed in a specific ratio, vitamin E or its derivatives have excellent stability, foam well, and can be stored at medium to high temperatures. Patent Document 2 (Japanese Patent No. 4,496,429) proposes that a dentifrice composition having excellent formulation stability can be obtained.
However, with conventional techniques, it has been difficult to achieve both the oral biofilm bactericidal effect and the stability of vitamin E, and to obtain an oral composition that has both of these properties.

Patent No. 6413815 Patent No. 4496429

The present invention was made in view of the above circumstances, and aims to provide an oral composition that has an excellent oral biofilm bactericidal effect, contains vitamin E stably even after storage, and has excellent stability. purpose.

As a result of intensive studies to achieve the above object, the present inventors have developed an oral composition by combining a specific nonionic bactericide, a specific anionic surfactant, vitamin E, and pyrrolidone carboxylic acid or its salt. It has been found that when blended, the oral biofilm bactericidal effect is excellent, and vitamin E is stably blended even after storage, resulting in excellent stability.
That is, in the present invention, (A) isopropyl methylphenol, (B) one or more selected from acylamino acids, acyl taurine, and salts thereof, and (C) tocopherol, esters thereof with organic acids, and salts thereof. By providing an oral composition containing one or more types and (D) pyrrolidone carboxylic acid or its salt, the oral biofilm bactericidal effect of the component (A) is enhanced, and an excellent oral biofilm bactericidal effect is achieved, and It was discovered that component (C), which is vitamin E, is stably blended even after storage, and the stability of component (C) is excellent, leading to the present invention.

More specifically, when component (A) is combined with component (B) in an oral composition, the biofilm bactericidal effect of component (A) is enhanced and an excellent biofilm bactericidal effect can be provided. However, when component (C) was further blended, the residual rate of component (C) decreased over time, resulting in a problem that its stability deteriorated. However, when component (D) is further added and components (A), (B), (C), and (D) are combined and blended, component (D) As mentioned above, by combining components (A), (B), (C) and (D), it has an unexpected effect of improving the stability of component (C). The stability of the ingredients was well maintained without being impaired even after storage, and in addition to the effects of ingredient (C) such as promoting blood flow by activating the gums, we were able to exhibit a significantly superior biofilm sterilizing effect. .

As shown in the comparative example below, in Comparative Example 1, in which components (A), (B), and (C) were blended, but component (D) was not blended, polyoxyethylene hydrogenated castor oil was added. In Comparative Example 2, the stability of vitamin E was poor, and even though components (A) and (C) were blended, and component (D) was also blended, component (B) was not blended. The biofilm bactericidal effect was low. On the other hand, as shown in the examples, the dentifrice composition containing the components (A), (B), (C), and (D) of the present invention has excellent vitamin E stability and It had an excellent biofilm bactericidal effect.

Therefore, the present invention provides the following oral composition.
[1]
(A) isopropylmethylphenol,
(B) one or more selected from acyl amino acids, acyl taurine, and salts thereof;
An oral composition comprising (C) one or more selected from tocopherol, its ester with an organic acid, and a salt thereof, and (D) pyrrolidone carboxylic acid or a salt thereof.
[2]
0.01 to 1% by mass of component (A), 0.01 to 2% by mass of component (B), 0.01 to 1% by mass of component (C), and 0.1 to 10% by mass of component (D) % of the oral composition according to [1].
[3]
The oral composition according to [1] or [2], wherein the component (B) is sodium lauroylsarcosine and/or sodium lauroylmethyltaurate.
[4]
The oral composition according to any one of [1] to [3], wherein (D)/((A)+(B)) is 0.5 to 100 as a mass ratio.
[5]
The oral cavity composition according to any one of [1] to [4], which is a dentifrice composition.

According to the present invention, it is possible to provide an oral composition that has an excellent biofilm bactericidal effect, contains vitamin E stably even after storage, and has excellent stability. The oral composition of the present invention has an excellent biofilm bactericidal effect and also has effects such as promoting blood flow in the gums due to the component (C), so it is effective for preventing or suppressing periodontal disease.

The present invention will be explained in more detail below.
The oral composition of the present invention comprises (A) isopropyl methylphenol, (B) one or more selected from acylamino acids, acyl taurine, and salts thereof, and (C) tocopherol, esters thereof with organic acids, and salts thereof. and (D) pyrrolidone carboxylic acid or a salt thereof.

(A) Isopropylmethylphenol has a biofilm bactericidal effect.
Isopropylmethylphenol (3-methyl-4-isopropylphenol) that complies with the Quasi-drug Ingredients Standards 2006 (hereinafter referred to as "Geigaku-genki") can be used, and specifically, it is manufactured by Osaka Kasei Co., Ltd. Commercially available products such as those from

The blending amount of component (A) is preferably 0.01 to 1% (mass%, the same applies hereinafter) of the entire composition, more preferably 0.03 to 0.5%, still more preferably 0.05 to 0. It is 3%. When the blending amount is 0.01% or more, a sufficient biofilm sterilizing effect can be obtained. The content is preferably 1% or less from the viewpoint of ensuring the stability of component (C).

Component (B) is one or more selected from acylamino acids, acyl taurine, and salts thereof, and when used in combination with component (A), these enhance and improve the biofilm bactericidal effect. play an action. As component (B), acyl taurine or a salt thereof is preferable from the viewpoint of biofilm bactericidal effect.
The acylamino acid and the acyl taurine are each preferably an amino acid having a saturated or unsaturated acyl group having 8 to 18 carbon atoms, preferably 12 to 14 carbon atoms, or taurine. Specific examples of the saturated or unsaturated acyl group having the specific number of carbon atoms include an octyl group, a decyl group, a lauroyl group, a myristoyl group, a palmitoyl group, and a stearyl group.
Furthermore, the acyl amino acid and acyl taurine may be used in the form of a salt, and a salt of the above-mentioned acyl group-containing amino acid or taurine may also be used. Examples of the salt include alkali metal salts such as sodium and potassium salts, and organic amine salts such as monoethanolamine and triethanolamine.
Specific examples of component (B) include acylamino acids or salts thereof such as sodium lauroylsarcosine, and examples of acyltaurines or salts thereof include sodium lauroylmethyltaurate.
These can be used alone or in combination of two or more.
As the component (B), those that comply with external standards can be used. For example, acyl sarcosine sodium is Soipon SLP (sodium lauroyl sarcosine) manufactured by Kawaken Fine Chemicals Co., Ltd., and acyl taurine sodium is manufactured by Nikko Chemicals Co., Ltd. ) manufactured by NIKKOL LMT, LMT-P, etc. can be used.

The blending amount of component (B) is preferably 0.01 to 2% of the total composition, more preferably 0.05 to 2%, and most preferably 0.1 to 1.5%. When the blending amount is 0.01% or more, the biofilm bactericidal effect is sufficiently improved, and the blending amount is preferably 2% or less from the viewpoint of ensuring the stability of component (C).

Component (C) is tocopherol of vitamin E or a derivative thereof, and as the derivative, an ester of tocopherol with an organic acid or a salt thereof can be used.
Component (C) is a medicinal component that activates the gums by promoting blood flow and restoring tissue, and is an effective component for preventing or suppressing periodontal diseases such as gingivitis and periodontitis.

Examples of tocopherols include d-α-tocopherol, dl-α-tocopherol, β-tocopherol, γ-tocopherol, and δ-tocopherol.
As tocopherol derivatives, esters of tocopherol with organic acids such as acetic acid, nicotinic acid, succinic acid, and linolenic acid, and alkali metal salts thereof such as sodium salts and calcium salts can be used. Specifically, d-α-tocopherol acetate, dl-α-tocopherol acetate, d-α-tocopherol nicotinate, dl-α-tocopherol nicotinate, d-α-tocopherol succinate, dl-α-tocopherol succinate. , tocopherol calcium succinate, d-α-tocopherol linolenic acid, dl-α-tocopherol linolenic acid, and the like.
Among these, tocopherol, tocopherol acetate, and tocopherol nicotinate are preferred, and tocopherol acetate is particularly preferred from the viewpoint of the color tone and appearance of the preparation.
These can be used alone or in combination of two or more.
Tocopherol or its derivatives can be those that comply with the Japanese Pharmacopoeia (Japanese Pharmacopoeia), old cosmetic raw material standards (cosmetic raw materials), or external standards. Specifically, tocopherols manufactured by DSM Nutrition Japan, Eisai Food, etc. Commercial products such as those manufactured by Chemical Co., Ltd. and BASF Japan Co., Ltd. may be used.

The amount of component (C) to be blended is preferably 0.01 to 1% of the total composition, more preferably 0.03 to 1%, and even more preferably 0.03 to 0.5%. When the amount is 0.01% or more, effects such as promotion of blood flow in the gingiva can be sufficiently obtained, and when the amount is 1% or less, it is preferable from the viewpoint of ensuring stability.

(D) Pyrrolidone carboxylic acid or its salt acts as a stabilizer for component (C), improves the specific decrease in stability of component (C) caused by components (A) and (B), and maintains stability even after storage. It has the effect of ensuring stability.
As the pyrrolidone carboxylic acid or its salt, pyrrolidone carboxylic acid or its sodium salt can be used. Specifically, it is possible to use a material that complies with external standards, such as AJIDEW N-50 (50% aqueous solution) manufactured by Ajinomoto Healthy Supply Co., Ltd.

The amount of component (D) to be blended is preferably 0.1 to 10% of the total composition, more preferably 0.5 to 10%, and even more preferably 1 to 5%. When the blending amount is 0.1% or more, the stability of component (C) is sufficiently excellent. When it is 10% or less, the off-taste derived from the component (D) itself is sufficiently suppressed.

The oral composition of the present invention has a quantitative ratio (D)/((A) of components (A), (B), and (D) from the viewpoint of the biofilm bactericidal effect and the stability of component (C). +(B)) is preferably from 0.5 to 100 as a mass ratio, more preferably from 1.5 to 50, even more preferably from 2 to 15, and most preferably from 3 to 10. When the mass ratio of (D)/((A)+(B)) is within the above range, the biofilm bactericidal effect and the stability of component (C) are even more excellent.

In addition, (B)/(A), which indicates the quantitative ratio of components (A) and (B), is preferably 1.0 to 40 as a mass ratio from the viewpoint of biofilm bactericidal effect and stability of component (C). , more preferably 1.5 to 30, still more preferably 2 to 12.
(C)/((A)+(B)), which indicates the quantitative ratio of components (A), (B), and (C), is the mass ratio from the viewpoint of biofilm bactericidal effect and stability of component (C). It is preferably from 0.05 to 3, more preferably from 0.15 to 2, even more preferably from 0.15 to 1.
(D)/(C), which indicates the quantitative ratio of components (C) and (D), is preferably 0.5 or more as a mass ratio, more preferably 1.0 or more, from the viewpoint of the stability of component (C). , more preferably 10.0 or more, and although the upper limit is not particularly limited, it is preferably 200 or less, more preferably 100 or less, still more preferably 50 or less.
In the present invention, the mass ratio of (D)/((A)+(B)), (B)/(A), (C)/((A)+(B)), (D)/(C) are within the above ranges, the biofilm bactericidal effect and the stability of component (C) will be even more excellent.

The oral composition of the present invention is particularly suitably prepared as a dentifrice composition such as toothpaste. In addition to the above-mentioned components, other known components can be added as needed within a range that does not impede the effects of the present invention. For example, a toothpaste can contain an abrasive, a binder, a thickening agent, a surfactant, and if necessary, a sweetener, a coloring agent, a preservative, a fragrance, and an active ingredient. In addition, the amount (%) shown below is the amount added to the entire composition.

Abrasives include silica-based abrasives such as anhydrous silicic acid, precipitated silica, aluminosilicate, and zirconosilicate, calcium phosphate-based compounds such as dicalcium phosphate dihydrate or anhydrate, calcium carbonate, and synthetic resin-based abrasives. Examples include agents. The amount of abrasive is usually 2 to 50%, particularly 10 to 40%.

Examples of thickeners include sugar alcohols such as sorbitol and xylit, and polyhydric alcohols such as glycerin and propylene glycol. The content of the thickening agent is usually 5 to 50%, particularly 10 to 30%.

The binder can be an organic or inorganic binder. Specifically, organic binders include sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, alginic acid or its derivatives, gums such as xanthan gum, carrageenan, polyvinyl alcohol, and sodium polyacrylate.Inorganic binders include gelling. Examples include (thickening) silica and gelling (thickening) aluminum silica. The amount of the binder added is usually 0.1 to 10%, particularly 0.1 to 5%. Note that organic binders are particularly preferred, and the blending amount of the organic binder is preferably 0.1 to 5%, particularly 0.5 to 3%.

As optional surfactants, anionic surfactants, nonionic surfactants, cationic surfactants, and amphoteric surfactants other than component (B) can be blended.
Examples of anionic surfactants include alkyl sulfates such as sodium lauryl sulfate.
Nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, sugar alcohol fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, etc. Examples include polyoxyethylene fatty acid ester, polyoxyethylene higher alcohol ether, and fatty acid alkanolamide.
Examples of the cationic surfactant include alkyl ammonium type surfactants and quaternary ammonium salt types such as alkylbenzylammonium salts.
Amphoteric surfactants include acetic acid betaine type such as alkyl betaine and fatty acid amidopropyl betaine, imidazolinium betaine type (alkyl (imidazole) type.
The blending amount of these surfactants is usually 0 to 10%, particularly 0.1 to 5%.

Examples of sweeteners include sodium saccharin.
Examples of the coloring agent include Blue No. 1, Yellow No. 4, and titanium dioxide.
Examples of the preservative include paraoxybenzoic acid esters such as methylparaben (methyl paraoxybenzoate), benzoic acid or salts thereof, and the like.

Fragrances include peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, lime. Oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie oil Natural fragrances such as , yuzu oil, iris concrete, absolute peppermint, absolute rose, orange flower, etc., and processing of these natural fragrances (front distillation cut, rear distillation cut, fractional distillation, liquid-liquid extraction, essence formation, powder fragrance) menthol, carvone, anethole, cineole, methyl salicylate, cinnamic aldehyde, borneol, camphor, eugenol, 3-l-menthoxypropane-1,2-diol, thymol, linalool, linaryl acetate, limonene , menthone, menthyl acetate, N-substituted-paramenthane-3-carboxamide, pinene, octylaldehyde, citral, pulegone, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allylcyclohexanepropionate, methyl anthranilate, Single flavors such as ethylmethylphenylglycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cyclotene, furfural, trimethylpyrazine, ethyl lactate, ethyl thioacetate, strawberry flavor, apple flavor, banana flavor , pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, mixed fruit flavor, tropical fruit flavor, etc., and can be used in combination with known flavor materials used in oral compositions. .
Although the blending amount of the fragrance is not particularly limited, it is preferable that the above-mentioned fragrance material is used in the composition in an amount of 0.000001 to 1%, and the fragrance using the above-mentioned fragrance material is used in the composition in an amount of 0.000001 to 1%. It is preferred to use 1-2%.

Optional active ingredients include ingredients other than ingredients (A) and (C), such as fluorine-containing compounds such as sodium fluoride and sodium monofluorophosphate, anti-inflammatory agents such as tranexamic acid and allantoin, and enzymes such as dextranase. , water-soluble phosphoric acid compounds, sodium chloride, potassium nitrate, aluminum lactate, ascorbic acid, plant extracts, anti-tartar agents, and anti-plaque agents. These active ingredients can be blended in an effective amount within a range that does not impede the effects of the present invention.

EXAMPLES Hereinafter, the present invention will be specifically explained by showing Examples, Comparative Examples, and Prescription Examples, but the present invention is not limited to the following Examples. In addition, in the following examples, % indicates mass % unless otherwise specified.

[Examples, comparative examples]
Dentifrice compositions (toothpaste) having the compositions shown in Tables 1 to 3 were prepared by a conventional method and evaluated by the following method. The results are also listed in the table.
The dentifrice compositions of Examples in the table had effects such as promoting blood flow in the gums derived from component (C).

(1) Stability of vitamin E (tocopherol or its derivatives) As an evaluation sample, a dentifrice composition was filled into a laminate tube container with a diameter of 8 mm and stored at 60°C or -5°C for one month. After allowing these to reach room temperature, 10g of them were collected, extracted with methanol, and then vitamin E was quantified by the absolute calibration curve method using HPLC (high performance liquid chromatography) using the equipment and test conditions described below.
The initial value is the quantitative value (%) of vitamin E in the dentifrice composition after being stored at -5°C for one month, and the quantitative value of vitamin E contained in the composition after being stored at 60°C for one month. Using the value (%) as the evaluation sample value, the residual rate of vitamin E was calculated using the following formula, and the stability of vitamin E over time was evaluated.
Vitamin E residual rate (%)
= {Evaluation sample value (%) / Initial value (%)} x 100
Regarding the stability of vitamin E, the residual rate of vitamin E calculated using the above formula is preferably 87% or more, more preferably 88% or more, even more preferably 90% or more, particularly preferably 92% or more, particularly preferably 95% or more. .

Equipment/pump used: Shimadzu Corporation, LC-20AD
・Sample introduction part: Manufactured by Shimadzu Corporation, SIL-20AC
・Detector: Shimadzu Corporation, SPD-20A
・Column constant temperature bath: Manufactured by Shimadzu Corporation, CTO-20AC
・Eluent flow rate: 1mL/min
Test conditions/detector: Ultraviolet absorption photometer (measurement wavelength: 273 nm)
・Column: COSMOSIL 5C18-MS-II
・Column temperature: 40℃
・Eluent: methanol

(2) Evaluation method of biofilm bactericidal effect Oral bacteria include Actinomyces viscosus ATCC43146, Fusobacterium nucleatum ATCC10953, and Porphyromonas gingivalis. gingivalis) ATCC33277 contains 5 mg/L hemin (Sigma The cells were cultured using Todd Hevit Broth (manufactured by Becton and Dickinson) (THBHM) containing 1 mg/L of vitamin K (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.). Veillonella parvula ATCC 17745 was cultured using Todd Hewitt Broth (manufactured by Becton and Dickinson) (THBL) containing 1.26% sodium lactate (manufactured by Sigma). The culture was performed overnight at 37° C. anaerobically (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen). After culturing, the bacterial solution was collected by centrifugation (8,000 g x 10 min). Each centrifuged bacteria was resuspended in basal medium mucin culture medium (BMM).
A hydroxyapatite (HA) plate (manufactured by Asahi Kogaku Co., Ltd.) with a diameter of 7 mm and a thickness of 3.5 mm was treated with unstimulated human saliva filtered through a 0.45 μm filter for 4 hours and used as a model biofilm production carrier. was placed at the bottom of a 24-hole multi-plate (manufactured by Sumitomo Bakelite Co., Ltd.). The above-mentioned four strains prepared at 1×10 ⁷ cfu/mL (cfu: colony forming units) with BMM were inoculated into this, and the cells were incubated at 37°C under anaerobic conditions (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen). After continuous cultivation for 6 days, a model biofilm containing a mixture of 4 bacterial species was formed on the surface of the HA plate.

After forming a biofilm, the culture medium was removed and the biofilm-adhered HA plate was treated with 0.5 mL of centrifuged supernatant obtained by diluting a dentifrice composition 3 times with distilled water as an evaluation sample for 3 minutes ( As a control, phosphate buffered saline (PBS, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was treated in the same way), washed 6 times with 1 mL of PBS, and then transferred to 4 mL of physiological saline. The biofilm was dispersed using an ultrasonic homogenizer. This biofilm dispersion was serially diluted 10 times with physiological saline, 50 μL was spread on a blood agar medium, anaerobic culture was performed for one week, and the number of colonies that grew was counted.
The ratio (%) of the number of colonies in the evaluation sample to the number of colonies in the control was calculated using the following formula, and the penetrating sterilizing effect on biofilm (biofilm sterilizing effect) was evaluated.
Biofilm bactericidal effect (%)
= {number of colonies in evaluation sample/number of colonies in control}×100
The biofilm bactericidal effect calculated using the above formula is preferably less than 1%, more preferably 0.2% or less, and even more preferably 0.1% or less.

Details of the raw materials used are shown below.
(A) Isopropylmethylphenol;
3-Methyl-4-isopropylphenol, conforming to foreign regulations, manufactured by Osaka Kasei Co., Ltd. (B)
(B-1) Sodium lauroylmethyltaurate;
LMT-P, conforming to foreign standards, manufactured by Nikko Chemicals Co., Ltd. (B-2) sodium lauroyl sarcosine;
Soipon SLP, conforming to external standards, manufactured by Kawaken Fine Chemicals Co., Ltd. (C) Vitamin E;
dl-α-tocopherol acetate, Japanese Pharmacopoeia compliant product, DSM Nutrition Japan Co., Ltd. (D) Sodium pyrrolidone carboxylate;
AJIDEW N-50 (50% aqueous solution), conforms to foreign regulations,
Manufactured by Ajinomoto Healthy Supply, Inc. Note that the numerical values indicating the amount of sodium pyrrolidone carboxylate (D) in Tables 1 to 3 and in the formulation examples described below are pure amounts.
Details of the composition of the fragrance are as described below.

Composition of fragrance;
Menthol 20
Peppermint oil 30
Anethole 10
Borneol 5
Camphor 5
Eugenol 5
Ethanol 25
Total 100%

Next, a prescription example will be shown.
A toothpaste with the following composition was prepared using the same raw materials as in the example, and the results of evaluation using the same method are also listed. In addition, these toothpastes had effects such as promoting blood flow in the gums derived from the component (C).

[Formulation Example 1] Toothpaste (A) Isopropylmethylphenol 0.2
(B) Sodium lauroylmethyltaurate 0.5
(C) Vitamin E 0.2
(D) Sodium pyrrolidone carboxylate 4.0
Abrasive silica 15
Thickening silica 5.0
Polyoxyethylene (5) hydrogenated castor oil 2.0
Propylene glycol 5.0
Sorvit 28
Xanthan gum 1.0
Sodium polyacrylate 0.5
Sodium alginate 0.5
Tranexamic acid 0.1
Sodium fluoride 0.32
Saccharin sodium 0.1
Fragrance 1.5
purified water balance
Total 100%
Mass ratio of (D)/((A)+(B)); 5.7
Vitamin E stability: 95%
Biofilm bactericidal effect: 0.04%

[Formulation Example 2] Toothpaste (A) Isopropylmethylphenol 0.05
(B) Sodium lauroylmethyltaurate 0.3
(B) Sodium lauroyl sarcosine 0.4
(C) Vitamin E 0.05
(D) Sodium pyrrolidone carboxylate 2.5
Abrasive silica 20
Thickening silica 3.0
Polyoxyethylene (20) hydrogenated castor oil 1.0
Polyoxyethylene (5) stearyl ether 2.0
Propylene glycol 3.0
Sorvit 21
Xanthan gum 1.5
Sodium polyacrylate 0.3
Sodium alginate 0.3
Sodium fluoride 0.32
Saccharin sodium 0.15
Fragrance 1.3
purified water balance
Total 100%
Mass ratio of (D)/((A)+(B)); 3.3
Vitamin E stability: 95%
Biofilm bactericidal effect; 0.15%

Claims (5)

(A) isopropylmethylphenol,
(B) one or more selected from acyl amino acids, acyl taurine, and salts thereof;
An oral composition comprising (C) one or more selected from tocopherol, its ester with an organic acid, and a salt thereof, and (D) pyrrolidone carboxylic acid or a salt thereof. 0.01 to 1% by mass of component (A), 0.01 to 2% by mass of component (B), 0.01 to 1% by mass of component (C), and 0.1 to 10% by mass of component (D) % of the oral cavity composition according to claim 1. The oral composition according to claim 1 or 2, wherein component (B) is sodium lauroylsarcosine and/or sodium lauroylmethyltaurate. The oral composition according to claim 1 or 2, wherein (D)/((A)+(B)) is a mass ratio of 0.5 to 100. The oral composition according to claim 1 or 2, which is a dentifrice composition.